Journal article
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
Abstract
Background: The Canadian Bleeding Disorders Registry (CBDR) captures data from 24 hemophilia treatment centers and patients directly. Nonacog beta pegol (N9-GP) was approved in Canada in 2018.
Objectives: To assess treatment outcomes following switching to N9-GP in a real-world setting.
Authors
Matino D; Iorio A; Keepanasseril A; Germini F; Caillaud A; Carcao M; Hews‐Girard J; Iserman E; James P; Lee A
Journal
Research and Practice in Thrombosis and Haemostasis, Vol. 6, No. 3,
Publisher
Elsevier
Publication Date
March 2022
DOI
10.1002/rth2.12661
ISSN
2475-0379